Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC

被引：0
|
作者：
Kim, C. [1 ]
Xi, L. [2 ]
Cultraro, C. [1 ]
Wei, F. [3 ]
Cheng, J. [3 ]
Shafiei, A. [4 ]
Pham, T. [2 ]
Roper, N. [1 ]
Akoth, E. [1 ]
Strom, C. [3 ]
Tu, M. [5 ]
Liao, W. [5 ]
Chia, D. [3 ]
Morris, C. [6 ]
Rajan, A. [1 ]
Bagheri, M. [4 ]
Jones, G. [6 ]
Wong, D. [3 ]
Raffeld, M. [2 ]
Guha, U. [1 ]
机构：
[1] NCI, Thorac & Gi Malignancies Branch, Ccr, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, Ccr, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] NIH, Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA
[5] Ezlife Bio Inc, Woodlind Hills, CA USA
[6] Inivata, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-mutant NSCLC; cDNA; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-27
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [21] Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
    Schmid, Sabine
    Stewart, Erin L.
    Martins-Filho, Sebastiao N.
    Cabanero, Michael
    Wang, Ao
    Bao, Hua
    Wu, Xue
    Patel, Deval
    Chen, Zhuo
    Law, Jennifer H.
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Leighl, Natasha
    Tsao, Ming-Sound
    Pugh, Trevor
    Bratman, Scott, V
    Sacher, Adrian
    Liu, Geoffrey
    CLINICAL LUNG CANCER, 2020, 21 (05) : E488 - E492
  • [22] Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
    Zang, Hongjing
    Qian, Guoqing
    Arbiser, Jack
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Fan, Songqing
    Sun, Shi-Yong
    MOLECULAR ONCOLOGY, 2020, 14 (04) : 882 - 895
  • [23] Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy
    Delasos, Lukas
    Berube, Bryan
    Nikoo, Maedeh Zokaei
    Wei, Wei
    Shapiro, Marc A.
    Hassan, Khaled Aref
    Stevenson, James
    Adjei, Alex A.
    Pennell, Nathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo V.
    Nilsson, Monique B.
    Robichaux, Jacqulyne
    Boyle, Theresa
    Hicks, J. Kevin
    Lovinger, Katherine L.
    Roarty, Emily
    Rinsurongkawong, Waree
    Tang, Ming
    Sun, Huiying
    Elamin, Yasir
    Lacerda, Lara C.
    Lewis, Jeff
    Roth, Jack A.
    Swisher, Stephen G.
    Lee, J. Jack
    William, William N., Jr.
    Glisson, Bonnie S.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki A.
    Gray, Jhanelle E.
    Heymach, John V.
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6195 - 6203
  • [25] Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report
    Rehman, Muneeb
    Kim, Chul
    Reuss, Joshua E.
    Kiedrowski, Lesli A.
    Garg, Ravin J.
    Liu, Stephen, V
    JCO PRECISION ONCOLOGY, 2021, 5 : 939 - 942
  • [26] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [27] Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC)
    Henick, Brian S.
    Goldberg, Sarah B.
    Narayan, Azeet
    Rossi, Chiara
    Rodney, Simon
    Kole, Adam J.
    Politi, Katerina A.
    Gettinger, Scott N.
    Herbst, Roy S.
    Patel, Abhijit
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms
    Piotrowska, Z.
    Stirling, K.
    Heist, R.
    Mooradian, M.
    Rizzo, C.
    Digumarthy, S.
    Lanuti, M.
    Fintelmann, F.
    Lennes, I.
    Farago, A.
    Gainor, J.
    Azzoli, C.
    Temel, J.
    Mino-Kenudson, M.
    Dias-Santagata, D.
    Corcoran, R.
    Shaw, A.
    Hata, A.
    Sequist, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1762 - S1762
  • [29] Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients
    Remon, J.
    Jovelet, C.
    Lacroix, L.
    Planchard, D.
    Mezquita, L.
    Howarth, K.
    Green, E.
    Plagnol, V.
    Morris, C.
    Rosenfeld, N.
    Caramella, C.
    Lepechoux, C.
    Nana, F. Aboubakar
    Botticella, A.
    Adam, J.
    Ferrara, R.
    Gazzah, A.
    Ngocamus, M.
    Soria, J.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S807 - S808
  • [30] Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient
    Pons-Tostivint, Elvire
    Hulo, Pauline
    Sagan, Christine
    Papazyan, Thomas
    Herbreteau, Guillaume
    Denis, Marc
    RESPIRATORY MEDICINE AND RESEARCH, 2024, 86
12345